Drug Trial Radar · NCT02760264
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Last checked: Nov 19, 2026Latest source record: Jan 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 2016
Primary completion
May 1, 2018
Study completion May 1, 2018
Sponsor
- Lead sponsor
- ReveraGen BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Pittsburgh; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute of Neurological Disorders and Stroke (NINDS); Cooperative International Neuromuscular Research Group
- First posted
- May 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 4 years, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and \< 7 years old.
Conditions
- Duchenne Muscular Dystrophy
Interventions
Vamorolone 0.25 mg/kg/dayDrug
Oral administration of 0.25 mg/kg/day daily for 14 days.
Vamorolone 0.75 mg/kg/dayDrug
Oral administration of 0.75 mg/kg/day daily for 14 days.
Vamorolone 2.0 mg/kg/dayDrug
Oral administration of 2.0 mg/kg/day daily for 14 days.
Vamorolone 6.0 mg/kg/dayDrug
Oral administration of 6 mg/kg/day daily for 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03Time frame: Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
University of California Davis
Davis, California
University of Florida
Gainesville, Florida
Nemours Children's Hospital
Orlando, Florida
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois
Duke University
Durham, North Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
Royal Children's Hospital
Melbourne, Australia
Sydney Children's Hospital
Westmead, Australia
Alberta Children's Hospital
Calgary, Alberta, Canada
Schneider Children's Medical Center
Petah Tikvah, Israel
Queen Silvia Children's Hospital
Gothenburg, Sweden
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.